MedTrace Logo

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

NCT05775289 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2026-05-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy.

Conditions

Interventions

DRUG

Tobemstomig

Participants will receive intravenous (IV) tobemstomig for four 21-day cycles

DRUG

Pembrolizumab

Participants will receive IV pembrolizumab four 21-day cycles

DRUG

Paclitaxel

Participants will receive IV paclitaxel Q3W for four 21-day cycles

DRUG

Pemetrexed

Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity

DRUG

Carboplatin

Participants will receive IV carboplatin Q3W for four 21-day cycles

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-LaRoche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2024-06-20
Completion
2026-06-01
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Brazil
  • France
  • Germany
  • Italy
  • Mexico
  • South Korea
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05775289 on ClinicalTrials.gov